The results of the AENEAS study highlighted that in first-line treatment of locally advanced or metastatic NSCLC patients with EGFR mutations, Almonertinib significantly prolonged median progression-free survival (PFS) (19.3 months versus 9.9 months) and duration of response (DOR) (18.1 months versus 8.3 months), with a more favorable safety profile compared to gefitinib (14). Here, EGFR is linked to non-small cell lung carcinoma.